Atossa Therapeutics Valuation
Is YAG2 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of YAG2 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate YAG2's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate YAG2's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for YAG2?
Key metric: As YAG2 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is YAG2's PB Ratio? | |
|---|---|
| PB Ratio | 2.2x |
| Book | US$73.68m |
| Market Cap | US$153.48m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | -2.7x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does YAG2's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 13.2x | ||
HPHA Heidelberg Pharma | 2.8x | -33.0% | €102.1m |
2INV 2invest | 1x | n/a | €62.7m |
VSC 4SC | 47.4x | n/a | €48.2m |
FYB Formycon | 1.5x | 31.5% | €848.4m |
YAG2 Atossa Therapeutics | 2.2x | 40.9% | €153.5m |
Price-To-Book vs Peers: YAG2 is good value based on its Price-To-Book Ratio (2.2x) compared to the peer average (13.2x).
Price to Book Ratio vs Industry
How does YAG2's PB Ratio compare vs other companies in the DE Biotechs Industry?
Price-To-Book vs Industry: YAG2 is good value based on its Price-To-Book Ratio (2.2x) compared to the European Biotechs industry average (2.4x).
Price to Book Ratio vs Fair Ratio
What is YAG2's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 2.2x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate YAG2's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €1.15 | €5.52 +380.4% | 22.5% | €6.63 | €3.79 | n/a | 3 |
| Nov ’25 | €1.26 | €5.06 +300.7% | 19.6% | €5.98 | €3.68 | n/a | 3 |
| Oct ’25 | €1.33 | €4.99 +276.5% | 19.6% | €5.90 | €3.63 | n/a | 3 |
| Sep ’25 | €1.19 | €4.96 +315.1% | 18.6% | €5.72 | €3.66 | n/a | 3 |
| Aug ’25 | €1.21 | €4.97 +309.7% | 18.6% | €5.74 | €3.67 | n/a | 3 |
| Jul ’25 | €1.19 | €4.97 +318.0% | 18.6% | €5.74 | €3.67 | n/a | 3 |
| Jun ’25 | €1.17 | €4.94 +323.3% | 17.7% | €5.56 | €3.71 | n/a | 3 |
| May ’25 | €1.41 | €4.36 +210.4% | 20.2% | €5.61 | €3.74 | n/a | 3 |
| Apr ’25 | €1.73 | €4.25 +145.3% | 18.0% | €5.34 | €3.71 | n/a | 3 |
| Mar ’25 | €0.89 | €4.25 +378.5% | 18.0% | €5.34 | €3.71 | n/a | 3 |
| Feb ’25 | €0.78 | €4.43 +469.3% | 17.9% | €5.22 | €3.63 | n/a | 2 |
| Jan ’25 | €0.92 | €4.43 +378.8% | 17.9% | €5.22 | €3.63 | n/a | 2 |
| Dec ’24 | €0.67 | €4.37 +551.3% | 15.8% | €5.06 | €3.68 | n/a | 2 |
| Nov ’24 | €0.63 | €4.52 +621.1% | 12.9% | €5.14 | €3.74 | €1.26 | 3 |
| Oct ’24 | €0.70 | €4.52 +543.5% | 12.9% | €5.14 | €3.74 | €1.33 | 3 |
| Sep ’24 | €0.72 | €4.29 +499.0% | 13.5% | €4.88 | €3.71 | €1.19 | 2 |
| Aug ’24 | €0.98 | €4.29 +336.9% | 13.5% | €4.88 | €3.71 | €1.21 | 2 |
| Jul ’24 | €1.24 | €4.29 +245.8% | 13.5% | €4.88 | €3.71 | €1.19 | 2 |
| Jun ’24 | €0.86 | €4.29 +402.0% | 13.5% | €4.88 | €3.71 | €1.17 | 2 |
| May ’24 | €0.56 | €4.38 +675.7% | 15.8% | €5.07 | €3.69 | €1.41 | 2 |
| Apr ’24 | €0.64 | €4.38 +586.7% | 15.8% | €5.07 | €3.69 | €1.73 | 2 |
| Mar ’24 | €0.69 | €4.72 +587.1% | 20.0% | €5.66 | €3.77 | €0.89 | 2 |
| Feb ’24 | €0.72 | €4.83 +568.3% | 20.0% | €5.79 | €3.86 | €0.78 | 2 |
| Jan ’24 | €0.48 | €4.83 +902.5% | 20.0% | €5.79 | €3.86 | €0.92 | 2 |
| Dec ’23 | €0.71 | €4.83 +578.2% | 20.0% | €5.79 | €3.86 | €0.67 | 2 |
| Nov ’23 | €0.99 | €5.40 +447.9% | 27.3% | €6.88 | €3.93 | €0.63 | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Aspen Pharmacare Holdings
R74.3b
Manufactures and supplies specialty and branded pharmaceutical products worldwide.
LDZA
R9.00
7D
0.6%
1Y
5.3%
Pharming Group
€492.8m
A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
PHGN
€0.71
7D
0.4%
1Y
-33.2%
Almirall
€1.8b
A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.
E2Z
€8.45
7D
1.1%
1Y
2.9%